Precision fermentation of dairy and egg proteins

01Overview and value chain

Markers: [EC: EU Novel Food Regulation (EC 2015/2283) | OECD: Food Systems | Regulator: FDA (USA), EFSA (EU), NHC (China)]

Precision fermentation of dairy and egg proteins uses engineered microorganisms — primarily the yeast Pichia pastoris and the filamentous fungus Trichoderma reesei — to express recombinant animal proteins identical to native beta-lactoglobulin, caseins, ovalbumin and lysozyme. The sector entered commercial maturity in 2025–2026, driven by FDA GRAS determinations in the US, regulatory approvals in Singapore and Israel, and the commissioning of fermentation capacity exceeding 100,000 litres per vessel. Compared with conventional dairy and egg production, these processes reduce greenhouse gas emissions by 90–97% and freshwater consumption by 95–99%.

Key directions of precision-fermented dairy and egg proteins:

1. Whey proteins (beta-lactoglobulin): Recombinant beta-lactoglobulin expressed in Trichoderma reesei or Pichia pastoris provides the melt, stretch and foam properties of dairy whey without lactose or cholesterol.
2. Casein micelles (alpha-s1, alpha-s2, beta, kappa): Co-expression of all four casein types with calcium-phosphate self-assembly into micelles, enabling genuine cheese melt and stretch.
3. Egg-white proteins (ovalbumin, conalbumin, lysozyme): Ovalbumin expressed in Pichia pastoris matches chicken egg-white in foaming, gelling and emulsification for bakeries and confectionery.
4. B2B ingredient platforms: Companies supply functional protein powders to food manufacturers as drop-in replacements for dairy and egg ingredients, with no animal husbandry at scale.

Sectoral value chain

[Gene design & strain engineering] ──> [Fed-batch fermentation (100 kL)]
                                                │
                                       (Secretion into broth)
                                                │
                                                ▼
[B2B protein powder] <── [Spray drying] <── [Ultrafiltration & polishing]

Value chain levels

Cross-cutting technologies of the sector:

• High-productivity secretory platforms: Genetic engineering of chaperone and secretion pathways in Pichia pastoris and Trichoderma reesei to achieve titres above 40 g/L of secreted target protein.
• AI-driven digital twins of bioreactors: Real-time prediction of yield, substrate consumption and oxygen transfer, reducing campaign duration by 15–20%.
• CRISPR-based chaperone engineering: Editing of yeast protein-folding pathways to prevent misfolding and aggregation of recombinant caseins during high-density fermentation.

02US

The United States is the global leader in regulatory approvals and venture investment, centred on FDA GRAS determinations for recombinant proteins.

Perfect Day commercial whey, Every Company ovalbumin, Onego Bio US plant

• Perfect Day beta-lactoglobulin: The first company to commercialise animal-free whey protein via Trichoderma reesei, achieving FDA GRAS status in 2020. Raised over $750M and supplies B2B protein to General Mills (Bold Cultr ice cream) and sport-nutrition brands.
• Every Company Every EggWhite: Recombinant ovalbumin expressed in Pichia pastoris, GRAS-approved and used in US bakeries for foam-stabilising and binding functions identical to dried egg-white powder.
• Onego Bio Bioalbumen: Finnish-American startup building a commercial-scale production plant in the US after raising over $40M. Its recombinant egg-white positions itself as a hedge against avian-influenza-driven egg-price volatility.

03CN

China treats precision-fermented proteins as a pillar of its Future Foods strategy, aiming to reduce dependency on imported milk powder and egg solids.

14th and 15th Five-Year Plans, Angel Yeast CMO platform, Changjin Biology

• Government prioritisation: The 14th and 15th Five-Year Plans (2021–2030) designate biotech food-ingredient production as a priority S&T direction, with Jiangnan University co-ordinating national grants for high-productivity yeast platforms.
• Angel Yeast CMO fermentation: The world’s largest yeast-extract manufacturer has invested in dedicated bioreactor capacity for contract precision fermentation of alternative proteins and enzymes.
• Changjin Biology: Shanghai-based startup that received safety certification in 2025 and operates a 3,000 m² R&D centre with pilot fermenters for milk and egg protein expression, targeting the domestic confectionery industry.

04EU

Europe has world-class industrial microbiology infrastructure but a slower regulatory pathway under the EU Novel Food Regulation, pushing many startups to launch first in the US or Asia.

Formo casein cheeses, Standing Ovation casein micelles, Novonesis platform provider

• Formo: Berlin-based leader in animal-free cheese, using Trichoderma to synthesise casein. In 2025–2026 Formo launched mozzarella and ricotta through German retailer REWE, with melt properties matching dairy cheese. EFSA dossier submitted.
• Standing Ovation: Paris-based company specialising in yeast-expressed casein. Co-expression vectors enable simultaneous synthesis of all four casein types followed by calcium-ion-triggered micelle self-assembly. Partnered with Bel Group (Babybel, La Vache qui rit).
• Novonesis: The global enzyme and fermentation leader (formed by the Novozymes–Chr. Hansen merger) provides CMO/OEM fermentation capacity for multiple PF protein startups, accelerating scale-up from lab to 100+ kL.

05Leading companies and research institutes

06Tech stack and innovations

The technological platform for precision-fermented dairy and egg proteins rests on four integrated layers: host engineering, high-titre fermentation, downstream purification and casein micelle self-assembly.

1. Production strains (Expression Hosts):

   • Pichia pastoris: methylotrophic yeast ideal for eukaryotic proteins (ovalbumin, casein) with high growth rates on simple media and efficient glycosylation-secretion pathways.
   • Trichoderma reesei: filamentous fungus with native secretory capacity exceeding 100 g/L for certain proteins, used by Perfect Day to reach ultra-high beta-lactoglobulin titres.
   • 2026 innovation: CRISPR editing of yeast chaperone pathways to prevent recombinant-protein misfolding during high-density fermentation.

2. Downstream purification (DSP):

   • Purification accounts for up to 50% of B2B protein cost. The target protein must be completely separated from fermentation media, host DNA and endogenous proteases.
   • 2026 state of the art: continuous-flow disc-stack centrifugation combined with tangential-flow microfiltration (TFF) on ceramic membranes, enabling water and heat recovery that cuts OpEx by 25%.

3. Casein micelle self-assembly:

   • Cheese melt requires assembly of four casein types (alpha-s1, alpha-s2, beta, kappa) into stabilised micelles cross-linked by calcium phosphate — a harder challenge than single-protein whey.
   • 2026 innovation: co-expression vectors (Standing Ovation) that synthesise all four caseins in optimal ratios, with calcium ions added in the downstream line for spontaneous micelle assembly.

07Value chains and production pipelines

Industrial production workflow of recombinant ovalbumin (egg-white protein) from Pichia pastoris seed train to spray-dried B2B powder (GMP / ISO 22000)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Inoculum seed train    │ ───> │ 2. Industrial fed-batch   │
│    (shake flask → pilot)  │      │    fermentation (100 kL)  │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Ultrafiltration (TFF)  │ <─── │ 3. Disc-stack             │
│    30 kDa concentration   │      │    clarification          │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Polishing (AEX /       │ ───> │ 6. Spray drying &        │
│    activated carbon)      │      │    B2B bagging (25 kg)   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Inoculum seed train

A cryopreserved Pichia pastoris strain carrying the chicken ovalbumin gene is thawed in a sterile cabinet and inoculated into a 500 mL shake flask, then scaled sequentially through 10 L and 1,000 L pilot fermenters. Duration: 5 days.

Stage 2: Industrial fed-batch fermentation (100,000 L)

The culture is transferred to a 100,000 L stainless-steel bioreactor. Glucose syrup provides the carbon source, followed by methanol feed to activate the AOX1 promoter that drives high-level ovalbumin synthesis. The process runs at 30 °C, pH 5.5, with constant aeration. Yeast secrete ovalbumin into the broth. Duration: 6–8 days.

Stage 3: Disc-stack clarification

The fermentation broth passes through disc-stack centrifuges. Yeast cells are separated and directed to animal-feed recovery; the supernatant containing dissolved ovalbumin is cooled to 4 °C to prevent proteolysis.

Stage 4: Tangential-flow ultrafiltration (30 kDa)

The clarified supernatant flows through a 30 kDa TFF membrane system. Water, salts and low-molecular-weight metabolites pass into the filtrate, while ovalbumin (45 kDa) is retained and concentrated 15–20×.

Stage 5: Polishing and DNA removal

The concentrated protein stream passes through an anion-exchange column or activated carbon filter to remove trace host DNA and pigment residues, meeting US and EU non-GMO purity standards.

Stage 6: Spray drying and B2B bagging

The purified ovalbumin concentrate is atomised through spray nozzles into a 160 °C drying chamber. Moisture evaporates instantly, yielding a free-flowing white powder with >95% protein content. It is packed in sterile 25 kg kraft bags for distribution to confectionery and bakery manufacturers.